SİSPLATİN OTOTOKSİSİTESİ

Yıl 2017, , 30 - 36, 24.04.2017

Burak Taş , Gökçe Şimşek

https://doi.org/10.24938/kutfd.306905

Cited By: 1

Öz

Ototoksisite
çeşitli ilaçlar ve kimyasal maddelerin koklea ve vestibüler organda oluşturduğu
hücresel dejenerasyon ve fonksiyon bozukluğudur. Sisplatin
(Cis-diamindiklorplatinum II) özellikle baş-boyun tümörlerinde, ürogenital
sistem, santral sinir sistemi, solunum sistemi ve özefagus kanserleri olmak
üzere birçok malign hastalığın tedavisinde erişkinlerde ve çocuklarda
kullanılmakta olan antineoplastik bir ajandır. Sisplatinin nefrotoksisite ve
geri dönüşümsüz ototoksisite dışında diğer önemli doz sınırlayıcı yan etkileri nörotoksisite,
gastrointestinal sistem ve kemik iliği toksisitesidir. Sisplatin ototoksik
etkisini reaktif oksijen ürünleri ve DNA hasarı ile göstermektedir. Sisplatin
ototoksisitesinde klinik olarak başlangışta yüksek frekanslarda, sonrasında
konuşma sesini de içeren düşük frekanslarda, bilateral, sensorinöral işitme
kaybı görülür. Günümüzde sisplatin bağımlı ototoksisiteyi önlemede standart bir
tedavi bulunmamaktadır. Bu derlemede sisplatin ototoksisitesinin tanımı, etki
mekanizması, güncel tedavi seçenekleri güncel literatür bilgileri eşliğinde
tartışılmıştır.

Anahtar Kelimeler

Sisplatin, ototoksisite, önleme, koklea, işitme kaybı, antioksidan

Kaynakça

• 1. Waissbluth S, Peleva E, Daniel SJ. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.Eur Arch Otorhinolaryngol. 2017;274(3):1187-96.
• 2. Seligmann H, Podoshin L, Ben-David J, Fradis M, Goldsher M.Drug-induced tinnitus and other hearing disorders. Drug Saf. 1996;14(3):198-212. Review.
• 3. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995 ;13(4):228-44.
• 4. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer. 1998 ;77(8):1355-62.
• 5. Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancer and normal hearing. Laryngoscope. 1988 ;98(8 Pt 1):858-64.
• 6. Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, Carpenter LS, Mai WY, Chintagumpala MM, South M, Grant WH 3rd, Butler EB, Woo SY. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int. J. Radiat. Oncol. Biol. Phys. 2002 1;52(3):599-605.
• 7. Hinojosa R, Riggs LC, Strauss M, Matz GJ. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol 1995 ;16(6):731-40.
• 8. Youn CK, Kim J, Jo ER, Oh J, Do NY, Cho SI. Protective effect of tempol against cisplatin-induced ototoxicity. Int J Mol Sci. 2016 18;17(11).
• 9. Peters RC, Mommersteeg PM, Heijmen PS. The electroreceptor organ of the catfish, Ictalurus melas, as a model for cisplatin-induced ototoxicity. Neuroscience. 1999;91(2):745-51.
• 10. Kopke, R.D., Liu, W., Gabaizadeh, R., Jacono, A., Feghali, J., Spray, D., Garcia, P., Steinman, H., Malgrange, B., Ruben, R.J., Rybak, L., Van de Water, TR.Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am. J. Otol. 1997 ;18(5):559-71.
• 11. Bánfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, Krause KH.NOX3, a superoxide-generating NADPH oxidase of the inner ear.J Biol Chem. 2004 29;279(44):46065-72.
• 12. Dehne N, Lautermann J, Petrat F, Rauen U, de Groot H.Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals.Toxicol Appl Pharmacol. 2001 ;174(1):27-34.
• 13. García-Berrocal JR, Nevado J, Ramírez-Camacho R, Sanz R, González-García JA, Sánchez-Rodríguez C, Cantos B, España P, Verdaguer JM, Trinidad Cabezas A. The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear. Br J Pharmacol. 2007 ;152(7):1012-20.
• 14. Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am. J. Otol. 2000 ;21(4):513-20.
• 15. Gosepath K, Gath I, Maurer J, Pollock JS, Amedee R, Förstermann U, Mann W. Characterization of nitric oxide synthase isoforms expressed in different structures of the guinea pig cochlea. Brain Res. 1997 ;747(1):26-33.
• 16. Kelly TC, Whitworth CA, Husain K, Rybak LP. Aminoguanidine reduces cisplatin ototoxicity. Hear Res. 2003 ;186(1-2):10-6.
• 17. Van Ruijven MW, de Groot JC, Hendriksen F, Smoorenburg GF. Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigs. Hear Res. 2005 ;203(1-2):112-21.
• 18. Liu W1, Staecker H, Stupak H, Malgrange B, Lefebvre P, Van De Water TR. Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Neuroreport. 1998 ;9(11):2609-14.
• 19. Liang F, Schulte BA, Qu C, Hu W, Shen Z. Inhibition of the calciumand voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. Neuroscience. 2005;135(1):263-71.
• 20. Laurell G, Bagger-Sjoback D. Degeneration of the organ of Corti following intravenous administration of cisplatin. Acta Otolaryngol. 1991;111(5):891-8.
• 21. Martín-Saldaña S, Palao-Suay R, Trinidad A, Aguilar MR, Ramírez-Camacho R, et al. Otoprotective properties of 6α-methylprednisolone-loaded nanoparticles against cisplatin: In vitro and in vivo correlation. Nanomedicine. 2016 ;12(4):965-76.
• 22. Doyle KJ, Bauch C, Battista R, et al. Intratympanic steroid treatment: a review. Otol Neurotol. 2004 ;25(6):1034-9.
• 23. Hargunani CA, Kempton JB, DeGagne JM, Trune DR. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol. 2006 ;27(4):564-9.
• 24. Özel HE, Özdoğan F, Gürgen SG, et al. Comparison of the protective effects of intratympanic dexamethasone and methylprednisolone against cisplatin-induced ototoxicity.J Laryngol Otol. 2016 ;130(3):225-34.
• 25. Waissbluth S, Salehi P, He X, Daniel SJ. Systemic dexamethasone for the prevention of cisplatin-induced ototoxicity.Eur Arch Otorhinolaryngol. 2013;270(5):1597-605.
• 26. Sun C, Wang X, Chen D, et al. Dexamethasone loaded nanoparticles exert protective effects against Cisplatin-induced hearing loss by systemic administration. Neurosci Lett. 2016 ;619:142-8.
• 27. Light LP, Silverstein H. Transtympanic perfusion: indications and limitations. Curr Opin Otolaryngol Head Neck Surg 2003;11(5):334-9.
• 28. Hughes AL, Hussain N, Pafford R, Parham K. Dexamethasone otoprotection in a multidose cisplatin ototoxicity mouse model.Otolaryngol Head Neck Surg. 2014 ;150(1):115-20.
• 29. Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs.Otolaryngol Head Neck Surg. 2007 ;137(5):747-52.
• 30. Salehi P, Akinpelu OV, Waissbluth S, et al. Attenuation of cisplatin ototoxicity by otoprotective effects of nanoencapsulated curcumin and dexamethasone in a guinea pig model.Otol Neurotol. 2014 ;35(7):1131-9.
• 31. Topdag M, Iseri M, Gelenli E, et al. Effect of intratympanic dexamethasone, memantine and piracetam on cellular apoptosis due to cisplatin ototoxicity.J Laryngol Otol. 2012 ;126(11):1091-6.
• 32. Watanabe KI, Hess A, Bloch W, Michel O. Nitric oxide synthase inhibitor suppresses the ototoxic side effect of cisplatin in guinea pigs. Anticancer Drugs. 2000 ;11(5):401-6.
• 33. Fetoni AR, Paciello F, Mezzogori D, et al. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer. 2015 ;113(10):1434-44.
• 34. Çetin R, Devrim E, Kılıçoglu B, et al. Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol. 2006 ;26(1):42-6.
• 35. Simşek G, Tokgoz SA, Vuralkan E, et al. Protective effects of resveratrol on cisplatin-dependent inner-ear damage in rats.Eur Arch Otorhinolaryngol. 2013 ;270(6):1789-93.
• 36. Wimmer C, Mees K, Stumpf P, et al. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor- 2 in cisplatin-induced ototoxicity. Otol Neurotol. 2004 ;25(1):33-40.
• 37. Wang J, Lloyd Faulconbridge RV, Fetoni A, et al. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology. 2003 ;45(3):380-93.
• 38. Muldoon LL, Pagel MA, Kroll RA, et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.Clin Cancer Res. 2000 ;6(1):309-15.
• 39. Song BB,Schacht J.Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo.Hear Res. 1996 ;94(1-2):87-93.
• 40. Hyppolito MA, de Oliveira JA, Rossato M. Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol. 2006 ;263(9):798-803.
• 41. Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope. 2004 ;114(3):538-42.
• 42. Teranishi M, Nakashima T, Wakabayashi T.Effects of alphatocopherol on cisplatin-induced ototoxicity in guinea pigs. Hear Res. 2001 ;151(1-2):61-70.
• 43. Fetoni AR, Sergi B, Ferraresi A, Paludetti G, Troiani D. Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. Acta Otolaryngol. 2004 ;124(4):421-6.
• 44. Celebi S, Gurdal MM, Ozkul MH, Yasar H, Balikci HH. The effect of intratympanic vitamin C administration on cisplatin-induced ototoxicity. Eur Arch Otorhinolaryngol. 2013 ;270(4):1293-7.
• 45. Kim SK, Im GJ, An YS, Lee SH, Jung HH, Park SY. The effects of the antioxidant α-tocopherol succinate on cisplatin-induced ototoxicity in HEI-OC1 auditory cells. Int J Pediatr Otorhinolaryngol. 2016;86:9-14.
• 46. Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005 ;314(3):1052-8.
• 47. Neuwelt EA,Pagel MA,Hasler BP,Deloughery TG,Muldoon LL.Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant aganist bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.Cancer Res. 2001 ;61(21):7868-74.
• 48. Fuertes MA, Castilla J, Alonso C, Pérez JM.Cisplatin biohemical mechanism of action:from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways.Curr Med Chem. 2003 ;10(3):257-66.
• 49. Feghali JG, Liu W, Van De Water TR. L-n acetyl-cysteine protection aganist cisplatin induced auditory neuronal and hair cell toxicity.Laryngoscope. 2001 ;111(7):1147-55.
• 50. Cakil B, Basar FS, Atmaca S, et al. The protective effect of Ginkgo biloba extract against experimental cisplatin ototoxicity: animal research using distortion product otoacoustic emissions. J Laryngol Otol. 2012 ;126(11):1097-101.
• 51. Lee SK, Oh KH, Chung AY, et al. Protective role of quercetin against cisplatin-induced hair cell damage in zebrafish embryos.Hum Exp Toxicol. 2015 ;34(11):1043-52.
• 52. Campbell K, Meech RP, Rybak LP, Hughes LF. The effect of D-methionine on cochlear oxidative state with and without cisplatin administration: mechanisms of otoprotection. J Am Acad Audiol. 2003 ;14(3):144-56.
• 53. Campbell K, Larsen DL, Meech RP, Rybak LP, Hughes LF. Glutathione ester but not glutathione protects against cisplatin-induced ototoxicity in a rat model. J Am Acad Audiol. 2003 ;14(3):124-33.